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paraseptal emphysema. And although neutrophil elastase activity
was not measured in this study, it might be speculated that
neutrophil elastase might be an important driver of paraseptal
emphysema development. A high amount of neutrophil elastase
activity has been linked to emphysema in humans and animals
(11). Moreover, increased elastase concentrations in sputum are
associated with increased risk of exacerbations (12), suggesting that
further understanding of the cellular and molecular orchestration
leading to emphysema might give insight that ultimately will
translate to modifying therapies for many people suffering from
COPD.
A question that arises from this work is how paraseptal
emphysema develops. The current notion for the pathologic
sequence of events from cigarette smoke to centrilobular
emphysema development starts with the inflammation of small
airway walls occurring in the center of the lobule. This process
leads to bronchiolar–alveolar attachments and surrounding
alveolar wall destruction. Because paraseptal emphysema occurs
adjacent to the pleura and septa and emphysema animal models
have marked changes in capillary segments (i.e., a higher number
of nonconnecting segments) on the pleural surface (13),
disruptions of pulmonary and/or pleural capillaries might also
contribute to paraseptal emphysema. It can be speculated that
pulmonary perfusion deficiency may lead to misbalanced
inflammatory response and tissue damage repair, resulting in
paraseptal emphysema.
In conclusion, the authors should be commended for this
elegant contribution to pathologic differences in the small airways
and cellular composition between paraseptal and centrilobular
emphysema. After a long time, this work brings paraseptal
emphysema to the center of the stage. n
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Rewiring the Immune Response in COVID-19
At the time of writing, the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) pandemic continues globally, with
nearly 15 million documented cases and more than 600,000 deaths
worldwide (1). Many countries have recently seen falls in the
number of confirmed cases and are beginning to cautiously
reopen following lockdown measures, whereas others are
experiencing a continued increase, “second waves” of infection,
or localized outbreaks following an initial reduction in cases (2, 3).
This pandemic represents the greatest public health, clinical,
and scientific challenge of our generation. Containing viral spread
has necessitated unprecedented social and economic change as
lockdowns only “temporarily” limit morbidity and mortality.
Identifying effective therapies and/or a vaccine remain our only
long-term solutions. Simply put, research is the only exit strategy
(2–5).
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Great progress has been made in understanding the
pathophysiology of coronavirus disease (COVID-19), the disease
caused by infection with SARS-CoV-2. Current concepts regard
COVID-19 as a biphasic illness: an initial viral phase with suggested
mean duration of 7 days followed by a “hyperinflammatory phase”
characterized by host-mediated organ damage and what is widely
referred to as a “cytokine storm” (6). A subset of patients with
COVID-19 display features consistent with hemophagocytic
lymphohistiocytosis (HLH), a fulminant hypercytokinemic syndrome
associated with multiorgan failure, cytopenias, and abnormal liver
function tests (7). There are, however, important differences in the
inflammatory profile of HLH and severe COVID-19, suggesting a
distinct pathophysiology. The respiratory manifestation of this
systemic inflammatory response is acute respiratory distress
syndrome (ARDS), and approximately 30% of patients with
COVID-19 from the initial series in Wuhan met criteria for ARDS (8).
This model of a hyperinflammatory syndrome occurring a week or
more after initial infection, leading to ARDS and a need for
mechanical ventilation, is further supported by the benefits of
dexamethasone in the recently published RECOVERY (Randomized
Evaluation of COVID-19 Therapy) trial (9). In this large, open-label,
United Kingdom–based trial, dexamethasone significantly reduced
COVID-19 mortality, with the largest effect in those requiring
mechanical ventilation (9). Most notably, in the supplementary
material, patients starting dexamethasone .7 days after symptom
onset demonstrated the most significant benefit, whereas those
treated in the first 7 days from symptom onset did not, validating the
proposed model of a late hyperinflammatory response that can be
therapeutically targeted.
In parallel to evidence of excess inflammation, reports of
profound viral-induced immunosuppression have emerged.
Specifically, deficient production of IFN-a and -b in blood is
reported in patients with severe disease, whereas a separate study
describes deficient IFN-g and TNF-a production (10, 11). Taken
together, severe COVID-19 appears to involve a delicate and
dynamic balance between excess inflammation and deficient
antiinflammatory and antiviral defenses.
The clinical presentation and immunological profile of
COVID-19 is therefore unique, and intensive research aimed at
characterizing this is ongoing. Most mortality is likely to be driven
by host responses rather than the virus, and there is clear evidence of
end-organ damage without evidence of viral invasion.
It is a remarkable triumph for clinical and translational research that
we know so much about the inflammatory response to SARS-CoV-2
only 6 months after the publication of its gene sequence. Nevertheless,
key questions remain about its pathophysiology: which components
of the inflammatory response are key “makers” rather than “markers,”
and what should be therapeutically targeted (12)? What inflammatory
characteristics distinguish between the different stages of disease,
and is this useful for risk stratification? Finally, some aspects of
the immune response remain less well characterized, and in
particular, the contribution of neutrophils to COVID-19 remains
unclear (13).
In this issue of the Journal, McElvaney and colleagues
(pp. 812–821), in a single-center study from Dublin, Ireland, aim to
provide fresh insight into the inflammatory response to COVID-19
(14). The study compared 20 patients requiring intensive care
admission for severe COVID-19 infection, 20 patients who were
hospitalized with stable COVID-19 infection (who did not require
ICU admission), and 15 healthy controls. The study confirmed
prior observations with elevated IL-6, IL-1b, soluble TNF receptor-
1, and IL-8 in the plasma of severe cases requiring ICU admission,
with elevated ratios of IL-6 and IL-1b to the antiinflammatory
cytokine IL-10. Metabolic reprogramming of immune cells refers to
complex alterations in cell metabolism, typically occurring upon
activation by external stimuli such as cytokines, leading to
profound change to their function. Neutrophil metabolic
reprogramming, or what the authors refer to as “rewiring,” is
reported in cystic fibrosis and other conditions in response to
inflammatory cytokines and low-level endotoxemia (15). These
observations are extended here with increased levels of HIF1-a,
PKM2, and cytosolic lactate in neutrophils from patients with
COVID-19. Importantly, however, precise mechanisms for these
effects remain undefined and are likely to be multifactorial
given the combined effects of proinflammatory mediators and
hypoxemia in severe COVID-19. Finally, the authors assessed
plasma alpha-1 antitrypsin (AAT), which is increased in COVID-19
compared with healthy controls. As IL-6 levels were higher
in the more severely ill patients with COVID-19, interestingly,
AAT was similarly increased, and the authors demonstrate that
positive outcomes were associated with a lower IL-6 relative to
AAT. The authors interpret this as meriting a trial of AAT
supplementation as AAT modulates inflammatory cytokine
production. Nevertheless, because the differences in IL-6:AAT
ratios are primarily driven by high IL-6, directly targeting IL-6
represents an equally logical strategy.
This work extends the characterization of COVID-19 by
proposing two novel potential targets: neutrophil metabolic
reprogramming and a relative AAT deficiency. There are .500
therapeutic trials in COVID-19 worldwide, and as recently reviewed
in the Journal (12), many duplicate existing trials or have limited
mechanistic work underpinning their choice of target or design.
Therefore, studies such as that presented here are important to
validate potential targets before embarking on therapeutic trials.
Demonstrating a mortality benefit with dexamethasone is a significant
breakthrough in antiinflammatory therapy for COVID-19; however,
the mortality rates of 17.8% (patients not requiring oxygen), 23.3%
(patients requiring oxygen) and 29.3% (patients requiring invasive
mechanical ventilation) remain high, and novel therapies will be
required (9). How should we prioritize? Anti–IL-6 (such as
tocilizumab), anti–IL-1b (such as anakinra), anti-TNF (e.g., infliximab),
IFN, or exogenous AAT? If the immune system has been rewired,
how do we know which wires to cut?
Although many more trials will report in 2020, the efficiency of
therapeutic development for COVID-19 will require a means
of prioritizing targets or many trials will never complete. In
this respect, translational studies such as this, in addition to proof-
of-concept phase 2 programs such as ACCORD (Accelerating
COVID-19 Research and Development) in the United Kingdom, are
the key to rapidly prioritize or discard potential therapies (16). n
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Subclinical Acute Kidney Injury Is Acute Kidney Injury and Should Not
Be Ignored
Serum creatinine (SCr) has long been known to be an imperfect
biomarker of kidney function (1). Although consensus definitions of
acute kidney injury (AKI) using SCr exist, they remain limited (2).
More specifically, owing to the nature of renal reserve, it often takes a
significant amount of (tubular) injury to translate into a rise in SCr
concentrations from baseline (3). Over the last decade, countless
investigations have sought to discover and validate biomarkers of AKI
that can identify patients who have early kidney injury (4). This concept
of elevation in kidney injury biomarkers in the absence of changes in
traditional markers (SCr and urine output [UO]) has been dubbed
“subclinical AKI” (5). However, given the mounting evidence and
multiple methods of detecting this injury, perhaps it needs a different
name because it will not be subclinical for much longer. It is with this
backdrop that, in this issue of the Journal, Dépret and colleagues (pp.
822–829) investigated plasma proenkephalin A (penKid), a 5-kD stable
breakdown product of enkephalins that accumulates in the setting of
reduced glomerular filtration (GFR) as a biomarker of subclinical AKI
in critically ill patients (6).
However, this newwork is not the first to look at subclinical AKI; in
2011, Haase and colleagues published a pooled multicenter analysis of
prospective studies focused on NGAL (neutrophil gelatinase–associated
lipocalin), an iron-binding protein that is upregulated in the setting of
ischemic kidney injury (7). In a compilation of 2,322 critically ill
patients, they demonstrated that patients who had elevated NGAL
concentrations in the absence of changes in SCr (NGAL[1]/SCr[2])
had similar outcomes compared with those with elevations in SCr in the
absence of changes in NGAL (NGAL[2]/SCr[1]). However, both these
groups experienced more adverse outcomes (need for renal replacement
therapy, longer length of ICU stay, and higher inpatient mortality)
compared with those with no elevations in SCr or NGAL.
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